BUZZ-MoonLake soars as FDA clears path for skin disease drug filing

Reuters01-08
BUZZ-MoonLake soars as FDA clears path for skin disease drug filing

** Shares of Swiss biotech MoonLake Immunotherapeutics MLTX.O rise 37.6% to $15.53 premarket

** Co says it has received positive feedback from the U.S. FDA that will allow the co to move forward with its BLA application for sonelokimab without more trials

** Co's sonelokimab targets hidradenitis suppurativa, a painful chronic skin condition causing lesions and scarring - MLTX

** The drug showed better outcomes vs placebo in over 1,000 patients, says co

** Co plans BLA submission in the second half of 2026

** A BLA or Biologics License Application is a formal request to the FDA seeking approval to market a biologic drug in the U.S. after demonstrating safety and effectiveness

** As of last close, stock down ~14% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment